Does serial administration of gadolinium‐based contrast agents affect patient neurological and neuropsychological status? Fourteen‐year follow‐up of patients receiving more than fifty contrast administrations

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F20%3A00008616" target="_blank" >RIV/00023884:_____/20:00008616 - isvavai.cz</a>

Result on the web

<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/jmri.26948" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1002/jmri.26948</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Does serial administration of gadolinium‐based contrast agents affect patient neurological and neuropsychological status? Fourteen‐year follow‐up of patients receiving more than fifty contrast administrations

Original language description

Gadolinium‐based contrast agents (GBCAs) have been in clinical use for ~30 years and have been considered relatively safe in terms of acute allergy‐like and chemotoxic reactions.1 The demonstration of increased signal intensity (SI) in the brain, particularly in the deep brain nuclei (dentate nucleus [DN] and globus pallidus [GP]) on unenhanced T1‐weighted images following cumulative GBCA dosing and evidence of the presence of gadolinium (Gd) in these nuclei (and elsewhere)2 has generated concern over potential long‐term detrimental effects of these agents, potentially leading to severe neurological deficits. As yet, however, no clinical manifestations of Gd toxicity or adverse clinical outcomes related to brain Gd retention have been observed following the repeated administration of any GBCA. Nevertheless, all linear GBCAs have been suspended in Europe with the exception of two substituted linear agents (MultiHance, Bracco Diagnostics, Princeton, NJ; and Primovist, Bayer Healthcare, Berlin, Germany) that are uniquely specific for liver imaging. The rationale for the suspension has been stated as: "to prevent any risks that could potentially be associated with gadolinium brain deposition."3 The basal ganglia and DN are primarily involved in cognitive processing and motor control.4 Damage to the DN and GP may therefore be expected to result predominantly in movement disorder manifestations such as resting tremor, rigidity, bradykinesia, and gait abnormalities, as well as cognitive impairment, depression, and neurobehavioral deficits. We therefore aimed to assess the neurological and neuropsychological status of four patients who received exceptionally large cumulative doses of GBCAs over many years at our center for the diagnosis and follow‐up of glioblastoma multiforme (GBM).

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

30224 - Radiology, nuclear medicine and medical imaging

Project

<a href="/en/project/NV18-04-00457" target="_blank" >NV18-04-00457: Detection of the dynamic of gadolinium retention in the brain after application of MR contrast agents using alteration of T1 and T2 relaxation times. Prospective study.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů